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A risk calculator algorithm to allow prediction of probabilities of 1- and 5-year recurrence 
and progression rates in individuals with pTa/pT1 bladder cancer has been proposed by 
the European Organisation for Research and Treatment of Cancer (EORTC) and was 
incorporated into the European Association of Urology guidelines in 2006. We attempted 
to validate this algorithm in a cohort of patients with known outcome. Prognostic data 
were collected from a consecutively presenting cohort of 109 patients with non–muscle 
invasive (pTa/pT1) transitional cell cancer (TCC) at a single institution between 1983 and 
1985. Using the same statistical models as in the EORTC original paper, predicted 
probabilities of 1- and 5-year recurrence and progression were calculated. Patients were 
divided into four risk groups for recurrence (Ir-IVr) and progression (Ip-IVp), respectively, 
using six prognostic criteria. These were then compared to the probabilities predicted in 
the EORTC algorithm. The predicted 1- and 5-year probabilities of recurrence were 
significantly higher in the study population as compared to the original EORTC algorithm 
for all four risk groups. The predicted 1-year probabilities for progression in groups 
Ip/IIIp and at 5-years for groups Ip/IIp were in accordance with the original algorithm, but 
were higher for the other progression groups. The concordance for the model of 
prediction using the study group for recurrence at 1 and 5 years was 62 and 63%, 
respectively, and for progression was 65 and 67%, respectively. We were unable to 
validate the proposed algorithm in our group of patients. Although our study has 
limitations that prevent firm conclusions on the validity of the algorithm, it does expose 
some of the drawbacks of standardised nomograms when applied to local clinical 
practice. 
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INTRODUCTION 
Prediction of outcome in patients with transitional cell cancer (TCC) of the bladder would markedly 
enhance clinical ability to tailor treatment to individuals, but this goal remains elusive. Prognostic 
parameters in non–muscle invasive TCC have been the focus of several publications[1,2,3,4,5], but none 
are sufficiently robust to be useful in routine clinical practice. 
In 2007, a risk calculator table based on six prognostic factors, including tumour size, number, pT 
category, grade, presence of in situ disease, and prior recurrence rate, was developed to predict recurrence 
and progression in individual patients with non–muscle invasive bladder cancer[6]. Data were extracted 
from a combined analysis of 2596 patients recruited to seven clinical trials undertaken by the 
genitourinary group of the European Organisation for Research and Treatment of Cancer (EORTC)[6]. 
The data were used to devise simple tables that would help to predict 1- and 5-year probability of 
recurrence and progression in individuals. Such tables may usefully be validated in different cohorts of 
population from different countries and urological institutions before entering routine clinical use. 
Our current study reports an attempt to validate the EORTC risk calculator tables using a 
consecutively presenting cohort of patients with non–muscle invasive bladder cancer and known 5-year 
outcome derived from a single institution in England. 
MATERIALS AND METHODS  
For our study, data were prospectively collected over a 5-year period from a cohort of patients who 
underwent consecutive transurethral resection (TUR) for new and recurrent bladder tumours at a single 
institution between April 1983 and February 1985. All patients included in the study had pTa/pT1 TCC as 
determined by formal histopathological examination. This cohort has been described previously[7]. This 
prospective data collection provided actual (observed) recurrence and progression rates at 1 and 5 years. 
As previously described by Sylvester et al.[6], six clinical and pathological variables used to develop 
the EORTC algorithm were pT category, grade, size, number, prior recurrence rate, and presence of CIS 
(carcinoma in situ). These variables were derived using a univariate and multivariate analysis of 2596 
superficial bladder cancer patients from seven EORTC trials. A weight (score) for each variable was 
obtained based on the coefficients of variables in the multivariate model. This allowed us to assign the 
individual patients in our study group a score for both recurrence and progression based on the presence 
or absence of these six prognostic variables. Based on the score, the patient was allocated to one of the 
four recurrence (Ir-IVr) and one of the four progression risk (Ip-IVp) subgroups previously defined by 
Sylvester et al. (Table 1). For example, a patient with a final recurrence score of five and a final 
progression score of five was assigned into the IIIr recurrence and IIp progression groups, respectively.  
TABLE 1 
Patient Groups as per Final Recurrence and Progression Scores in the Study Population 
Recurrence 
Groups  
Recurrence 
Score 
No.of Patients 
(n = 109) 
Progression 
Groups 
Progression 
Score 
No. of Patients 
(n = 109) 
Ir 0 2 Ip 0 27 
IIr 1–4 68 IIp 2–6 53 
IIIr 5–9 33 IIIp 7–13 26 
IVr 10–17 6 IVp 14–23 3 
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Using the same methodology as Sylvester et al., we then performed, using our study population, 
univariate analysis to identify prognostic clinical and pathological variables for recurrence and 
progression. Multivariate analysis, incorporating these prognostic variables, then generated predictive 
probabilities allowing direct comparison with the study population’s observed 1- and 5-year recurrence 
and progression rates, and comparison with the predictive probabilities generated using the original 
EORTC trial data. In this manner, we were able to validate the EORTC nomogram, both in terms of its 
predictive probabilities and identified prognostic clinical and pathological variables.  
Death before recurrence and progression was analysed as a competing risk. Three patients were lost 
to follow-up during the 5-year period. These were censored at their last documented cystoscopy and 
therefore included in the analysis. 
Statistics 
The Kaplan-Meier method[8] was employed to calculate predicted probabilities of recurrence and 
progression at 1 and 5 years, respectively. Harrell’s bias corrected concordance (c) index[9] (0 ≤ c ≤ 1) 
was calculated to assess the accuracy of predictions. The c index is a measure of the discriminatory power 
of the equation ranging from 0.5 to 1.0, with 1.0 as perfect and 0.5 as no better than chance. A Cox 
regression model was employed to identify the prognostic factors of recurrence and progression. All 
statistical analysis was performed using SAS 8.2 and R 2.2.0 software 
RESULTS 
Between April 1983 and February 1985, 173 patients underwent TUR for bladder tumours. After 
histological assessment to select only patients with pTa/pT1 TCC, our final study population totalled 109 
patients. Median follow-up was 5 years. Table 2 gives the demographic and clinical characteristics of this 
study group and compares them with the previously reported EORTC group[6]. Ninety-five patients had 
complete 5-year follow-up data. Of the remaining 14 patients, 11 died and three were lost to follow-up. 
The causes of death were: medical causes (n = 3), bladder cancer (n = 2), ruptured aortic aneurysm (n = 
1), carcinomatosis of unknown origin (n = 1), and unknown (n = 4).  
The proportion of patients with recurrence and progression at 5 years was 63.3 and 12.8%, 
respectively, with a median time to first recurrence of 10 months and a median time to first progression of 
60 months. For recurrence, the majority of patients were assigned either to risk groups II or III, whereas 
for progression, there were relatively equal numbers in risk group I and III, with the highest proportion in 
risk group II (Table 1). The observed proportion of patients who had recurrence at 5 years increased 
across the risk groups (I to IV). A similar trend was seen for observed 5-year progression (Table 3). The 
predicted probabilities for recurrence in all groups of the study population were higher than the EORTC 
predictions (Table 4). For progression, group IVp showed high progression rates, whereas groups Ip and 
IIp had comparable results to the EORTC algorithm. Group IIIp had comparable 1-year, but higher 5-year 
progression rates to the EORTC algorithm. 
Figs.1 and 2 show the Kaplan-Meier plots for time to first recurrence and time to first progression, 
respectively, for the study group, stratified according to the EORTC defined risk groups.  
The c index for recurrence was 0.62 for 1 year and 0.63 for 5 years. The c index for progression was 
0.65 and 0.67 for 1 and 5 years, respectively. 
Univariate and multivariate Cox regression analysis results are presented in Table 5. Number of 
tumours (>8), tumour size (≥3cm), T category (T1), and CIS (present) were identified as independent 
prognostic factors in our cohort. For example, the hazard ratio of recurrence and progression for a patient 
with a number of tumours >8 is 10.89 (95% CI: 2.40, 49.38) times that for a patient with a number of 
tumours of 8.  
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TABLE 2 
Patient Characteristics in Our Study Group and the EORTC Group 
 Study Group  
No. (%) 
EORTC Group 
No. (%) 
Total number of patients 109 2596 
Age 
<60 29 (26.6) 859 (33.1) 
61–70 35 (32.1) 890 (34.3) 
71-80 31 (28.4) 690 (26.6) 
>80 13 (11.9 118 (4.5) 
Unknown 1 (0.9) 39 (1.5) 
Gender 
Male 84 (77.1) 2044 (78.7) 
Female 25 (22.9) 515 (19.8) 
Intravesical treatment with single-dose mitomycin 
Yes 21 (19.3) 2035 (78.4) 
No 88 (80.7) 561 (21.6) 
Prior recurrence 
Primary  103 (94.4) 1405 (54.1) 
Prior recurrence (≤1 rec/year) 3 (2.7) 505 (19.5) 
Prior recurrence (>1 rec/year) 3 (2.7) 645 (24.8) 
Number of tumours 
Single 64 (58.7) 1465 (56.4) 
2–7 32 (29.3) 836 (32.2) 
≥8 13 (11.9) 255 (9.8) 
Size of tumours 
<1 cm 28 (25.6) 920 (35.4) 
<3 cm 36 (33.0) 1167 (45.0) 
≥3cm 43 (39.4) 464 (17.9) 
Unknown
 
2 (1.8) 45 (1.7) 
PT category 
Ta 78 (71.5) 1451 (55.9) 
T1 31 (28.5) 1108 (42.7) 
Presence of CIS 
No 100 (91.7) 2440 (94.0) 
Yes 9 (8.3) 113 (4.4) 
Grade of tumour 
G1/G2  98 (89.9) 2260 (87.1) 
G3 11(10.1) 271 (10.4) 
Follow-up(years) 
Median 5 3.9 
Maximum 5 14.8 
Recurrence 
No 40 (36.7) 1356 (52.2) 
Yes 69 (63.3) 1240 (47.8) 
Progression 
No 95 (87.2) 2317 (89.3) 
Yes 14 (12.8) 279 (10.7) 
Survival 
Alive 98 (90) 1743 (67.1) 
Dead 11(10) 279 (32.9) 
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TABLE 3 
Number of Study Group Patients According to EORTC Risk Group Scores for Recurrence and 
Progression and Observed Proportion of 5-Year Recurrence and Progression in the Study 
Population 
Recurrence 
Risk Group 
No. in 
Each 
Group 
Patients 
with 
Recurrence 
Observed  
5-Year 
Recurrence 
Proportion 
(%) 
Progression 
Risk Group 
No. in 
Each 
Group 
Patients. 
with 
Progression 
Observed  
5-Year 
Progression 
Proportion 
(%) 
Ir 2 1 50 Ip 27 0 0 
Iir 68 38 55.9 IIp 53 3 5.7 
IIIr 33 24 72.7 IIIp 26 10 38.5 
Ivr 6 6 100 IVp 3 1 33.3 
Total 109 69   109 14  
TABLE 4 
Comparing the Predicted Probabilities of Recurrence and Progression of Our Study Group with 
Original EORTC Algorithm 
 
No. of 
Patients 
1-Year Predicted Probabilities 
with (95% CI) (%) 
5-Year Predicted Probabilities 
with (95% CI)(%) 
Study Group Algorithm Study Group Algorithm 
Recurrence Groups      
Ir 2 0.0(0.0,0.0) 15(10,19) 100.0(100.0,100.0) 31(24,37) 
IIr 68 40.3(28.6,52.1) 24(21,26) 56.0(43.9,68.0) 46(42,49) 
IIIr 33 59.6(42.5, 76.7) 38(35,41) 77.7(52.5,92.9) 62(58,65) 
Ivr 6 100.0(100.0,100.0) 61(55,67) 100.0(100.0,100.0) 78(73,84) 
Progression Groups      
Ip 27 0.0(0.0, 0.0) 0.2(0,0.7) 0.0(0.0,0.0) 0.8(0.0,1.7) 
IIp 53 1.8(0.0,5.1) 1.0(0.4,1.6) 5.8(0.0,12.3) 6.0(5.0,8.0) 
IIIp 26 4.0(0.0,48.9) 5.0(4.0,7.0) 44.1(23.5,64.7) 17.0(14.0,20.0) 
IVp 3 33.3(0.0,86.6) 17.0(10.0,24.0) 33.3(0.0,86.6) 45.0(35.0,55.0) 
Note: Figures in bold print indicate that the predicted probabilities of the study group are in accordance with that of 
the algorithm. 
DISCUSSION 
Predicting the risk of recurrence and progression in non–muscle invasive bladder cancer has been the 
focus of much research, with the aim of individualised management for this group of patients. 
Conventionally, TCC has been divided into three risk groups (low, intermediate, and high), based on 
prognostic factors derived from multivariate analysis[10]. More recently, (updated) nomograms have 
been proposed to predict the probability of progression and recurrence in patients with Ta, T1, and/or CIS 
bladder TCC[11], which include additional criteria such as urinary NMP22, cytology, age, and gender.  
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FIGURE 1. Time to first recurrence. 
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FIGURE 2. Time to first progression. 
Sylvester’s algorithm[6], derived from seven EORTC trials and incorporated into the European 
Association of Urology guidelines in 2006, provides simple tables to predict the risk of TCC recurrence 
and progression in individuals. These, however, remain to be assessed within individual institutions 
enabling ,for example, validity for smaller cohorts and subsets of bladder cancer populations. Our study, 
based on a smaller cohort of bladder cancer patients from a single institution, is the first reported study 
attempting to validate the algorithm. 
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TABLE 5 
Cox Model Analysis of Time to Recurrence and Progression 
Variable 
Univariate Analysis Multivariate Analysis 
HR 
95% CI 
p Value HR 
95% CI 
p Value 
Lower Upper Lower Upper 
Number of tumours (2–7 vs. single) 1.34 0.45 3.99 0.6043 1.39 0.30 6.36 0.6750 
Number of tumours (>8 vs. single) 5.75 1.92 17.24 0.0018 10.89 2.40 49.38 0.0020 
Tumour size (≥3 cm vs. <3 cm) 0.40 0.11 1.45 0.1647 0.18 0.04 0.82 0.0262 
Prior recurrence (yes vs. no) 3.41 0.76 15.28 0.1087 4.59 0.68 30.93 0.1176 
T Category (T1 vs. Ta) 7.72 2.42 24.66 0.0006 11.60 2.33 57.72 0.0027 
CIS (yes vs. no) 4.45 1.39 14.24 0.0119 9.13 1.71 48.77 0.0097 
Grade (3 vs. 1 and 2) 5.70 1.76 18.40 0.0036 1.90 0.44 8.16 0.3868 
HR = hazard ratio. 
Some of the differences in outcome may be accounted for by differing patient characteristics 
(incidence of primary tumours, size, and pT category) between the two study groups (Table 2), e.g., only 
a small percentage of our study population received intravesical chemotherapy (19.3%) compared to 
Sylvester’s group (78.4%). The sample size of our study population, especially the small numbers in 
some individual risk groups, also influenced the study results. For most of the comparisons, the 
confidence intervals overlap – suggesting the possibility that the nomogram may be valid even though the 
median numbers are widely different. In addition, the Kaplan-Meir method, while accurate for calculating 
1-year predicted probabilities, might not be accurate when predicting the 5-year probabilities[12].  
Our study has the advantage of examining an unselected cohort of consecutive patients with non–
muscle invasive TCC as opposed to data originating from clinical trials in which patients are selected for 
interventions by stringent inclusion/exclusion criteria. As a single-centre study, it was possible to ensure 
that all bladder cancer patients within a given time period were included, reducing or avoiding selection 
bias that may play a role with the less exact reporting that may occur in multicentre registries. There was 
also a comprehensive record of tumour characteristics at initial cystoscopy in all patients, histology 
review by a single pathologist, and in 95% of the cases, muscle was present in the specimen, increasing 
accuracy of confirming pT category. All clinical parameters were collected and recorded by one person, 
minimising interobserver variability. Outcomes were also less likely to be influenced by intravesical 
chemotherapy as in the original EORTC study, a factor important when predicting prognosis, but not 
discussed in Sylvester’s original algorithm[13,14]. Statistical methods used for predicting the 
probabilities were similar to those used for the original EORTC algorithm. 
Although the original EORTC algorithm was intended to be universally applicable for all non–muscle 
invasive TCC, it cannot be applied to patients with diffuse lesions on TUR or CIS on histology, as scores 
could not be assigned to them for their size, numbers, or pT category and grade (with CIS). This is 
relevant considering that 10% of all CIS can present in a primary form without associated papillary 
tumour[15]. Also, the original algorithm measures two variables (tumour size and number) that are 
especially subjective and vary between different operators. There is also interobserver variation amongst 
histologists when evaluating the pT category and grade of TCC[16]. In addition, the fact that some of the 
progression predictions were in accordance with the original algorithm as opposed to the recurrence 
predictions reinforces the likelihood that recurrence and progression are influenced by additional 
variables other than those six selected for inclusion[17,18]. 
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CONCLUSIONS 
The primary objective of our study was to assess the applicability of the risk calculator tool and validate it 
against the existing EORTC algorithm in a cohort of consecutive patients from a single centre. Although 
the risk calculator was user friendly, there were marked differences between the predicted probabilities of 
recurrences in all the risk groups and some differences in the predicted probabilities of progression when 
compared to actual events. The low patient numbers in individual groups limits the ability to draw firm 
conclusions about the validity of the nomogram, but our study does expose some of the drawbacks of 
standardised prognostic algorithms derived from the outcome of prospective randomised trials, when 
applied to local clinical practice.  
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